Logo

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Share this

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Shots:

  • The company presents the ongoing program of SARS-CoV-2 mutation surveillance for STI-2020 currently in pre/ clinical development for COVID-19
  • The data provides evidence of maintained binding potency in in vitro assays including the Spike amino acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage- identified in the UK
  • Additional neutralizing Abs were identified that bind strongly to the B.1.1.7 & B.1.351 spike proteins and are under analyses for neutralization activities both in vitro and in vivo. Sorrento to unveils early in vitro results of diminished STI-2020 binding potency in assays including Spike proteins derived from viruses of the B.1.351 lineage- identified in SA

 ­ Ref: Sorrento | Image: Sorrento 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions